Celeris

Celeris Therapeutics is a deep learning-driven drug discovery company focused on the development of proximity-inducing compounds, specifically targeted protein degraders. The company utilizes its proprietary CelerisOne platform, which integrates AI-driven generative design with automated experimental validation to accelerate the discovery of PROTACs and molecular glues. Their pipeline primarily targets "undruggable" proteins involved in oncology and neurodegenerative diseases, such as Parkinson's. By combining computational prediction with high-throughput synthesis, Celeris aims to streamline the identification of potent degraders for complex disease targets. The company maintains a dual presence in the United States and Europe to leverage global talent in AI and drug discovery.